{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:08:15Z","timestamp":1780582095497,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejps.2021.105752","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T13:05:55Z","timestamp":1612962355000},"page":"105752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study"],"prefix":"10.1016","volume":"160","author":[{"given":"Rui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Chessari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Lanzarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bernareggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105752_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","article-title":"CINV: still troubling patients after all these years","volume":"26","author":"Aapro","year":"2018","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.ejps.2021.105752_bib0002","first-page":"1009","article-title":"Palonosetron as an anti-emetic and anti-nausea agent in oncology","volume":"3","author":"Aapro","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ejps.2021.105752_bib0003","unstructured":"Aloxi \u00ae Palonosetron HCl injection, n.d."},{"key":"10.1016\/j.ejps.2021.105752_bib0004","first-page":"1453","article-title":"Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial","volume":"21","author":"Boccia","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejps.2021.105752_bib0005","first-page":"413","article-title":"Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting","volume":"19","author":"De Leon","year":"2006","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.ejps.2021.105752_bib0006","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/annonc\/mdh047","article-title":"Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study","volume":"15","author":"Eisenberg","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejps.2021.105752_bib0007","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/jcph.1338","article-title":"Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting","volume":"59","author":"Gilmore","year":"2019","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ejps.2021.105752_bib0008","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1517\/14656566.4.12.2297","article-title":"Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis","volume":"4","author":"Grunberg","year":"2003","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.ejps.2021.105752_bib0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/07357900009038248","article-title":"Clinical Science Review: Comparative Review of 5-HT 3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting","volume":"18","author":"Hesketh","year":"2000","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.ejps.2021.105752_bib0010","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bph.12204","article-title":"Prolonged inhibition of 5- HT 3 receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization","volume":"169","author":"Hothersall","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejps.2021.105752_bib0011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14656566.2013.776541","article-title":"Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients","volume":"14","author":"Janelsins","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejps.2021.105752_bib0012","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00520-015-2657-1","volume":"23","author":"Karthaus","year":"2015","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.ejps.2021.105752_bib0013","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/0091270004268128","article-title":"Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms","volume":"44","author":"Kim","year":"2004","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ejps.2021.105752_bib0014","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1517\/14656566.2014.972366","article-title":"Palonosetron for the treatment of chemotherapy-induced nausea and vomiting","volume":"15","author":"Navari","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.ejps.2021.105752_bib0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0091270004264641","article-title":"Pharmacokinetic and Safety Evaluation of Palonosetron, a 5-Hydroxytryptamine-3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects","volume":"44","author":"Stoltz","year":"2004","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ejps.2021.105752_bib0016","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0091270004264641","article-title":"Pharmacokinetic and Safety Evaluation of Palonosetron, a 5-Hydroxytryptamine-3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects","volume":"44","author":"Stoltz","year":"2004","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ejps.2021.105752_bib0017","article-title":"Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis","volume":"13","author":"Tricco","year":"2015","journal-title":"BMC Medicine"},{"key":"10.1016\/j.ejps.2021.105752_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"Zhang","year":"2018","journal-title":"Annals of Oncology"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:57:47Z","timestamp":1760529467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":18,"alternative-id":["S0928098721000543"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105752","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105752"}}